Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

ABSTRACT: Pancreatic neuroendocrine tumors (pNETs) are unique, slow-growing malignancies whose molecular pathogenesis is incompletely understood. With rising incidence of pNETs over the last four decades, larger and more comprehensive 'omic' analyses of patient tumors have led to a clearer picture of the pNET genomic landscape and transcriptional profiles for both primary and metastatic lesions. In pNET patients with advanced disease, those insights have guided the use of targeted therapies that inhibit activated mTOR and receptor tyrosine kinase (RTK) pathways or stimulate somatostatin receptor signaling. Such treatments have significantly benefited patients, but intrinsic or acquired drug resistance in the tumors remains a major problem that leaves few to no effective treatment options for advance

SUBMITTER: Maharjan CK 

PROVIDER: S-EPMC8533967 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature